Two Sigma Securities’s ADC Therapeutics ADCT Stock Holding History

Two Sigma Securities’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15,048	Closed	-$29.9K	–	1410
2024 Q4	$29.9K	Buy	+15,048	New	+$39.4K	﹤0.01%	1252

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Securities's ADCT Position: Q1 2025 in Review

Two Sigma Securities sold out of ADC Therapeutics (ADCT) in Q1 2025, closing a stake of 15,048 shares — an estimated $29.9K sold.

Two Sigma Securities first reported a position in ADCT in Q4 2024 and held it in 1 quarter. The position peaked at $29.9K in Q4 2024. 82 funds tracked by Wall St. Rank hold ADCT as of Q1 2025.

Two Sigma Securities reported no remaining ADC Therapeutics position as of Q1 2025 after selling out during the quarter.
Two Sigma Securities sold 15,048 ADC Therapeutics shares in Q1 2025, an estimated $29.9K.
Two Sigma Securities first reported a position in ADC Therapeutics in Q4 2024 and held it in 1 quarter.
Two Sigma Securities's ADC Therapeutics position peaked at $29.9K in Q4 2024.
82 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2025.

Based on Two Sigma Securities's 13F filing for Q1 2025, filed 15 May 2025.